SecBot SecBot
8-K ·Filed Nov 6, 2026

MRNA

Moderna, Inc.
BULLISH
Impact 7/10
Horizonimmediate Processed10d 19h ago SEC0001682852-26-000194
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant revenue beat and raised guidance reflect strong execution on international COVID vaccine deliveries and cost discipline. Watch for the November 12 Analyst Day for further pipeline details, particularly intismeran regulatory submission timing and propionic acidemia data.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

MRNA drug pipeline →

mRNA-1010

▲ Bullish Named in this 8-K
Impact
Phase
Filed / PDUFA (Phase 3 completed)
Time to market
PDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.
Next catalyst
None dated

What to watchWatch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$254.19
T+0 close · Nov 6, 2026 · via day close
Latest settled
−12.12%
T+5 · $223.37
Vs SPY
−14.72%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $254.19entry
  2. T+1 · 8d ago +5.83%α +3.46% · $269.00
  3. T+5 · 4d ago −12.12%α −14.72% · $223.37
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and GAAP diluted EPS of $0.38 (consensus $-1.25), a significant beat driven by higher COVID vaccine sales in international markets. The company raised its full-year 2026 revenue growth outlook to 15%-25% from up to 10%, improved its year-end cash balance forecast to $8.1B-$8.3B, and highlighted the FDA approval of mFLUSIVA and positive Phase 3 data for intismeran in melanoma.

Key Financial Metrics

EPS
$0.38
est −$1.25 · +130.4%
Revenue
$1.3B
est $890.2M · +47.5% · +29.2% YoY
Rating
strong beat
Guidance
15% to 25% growth from 2025 revenue
raised

Key Facts

  • Q3 2026 total revenue $1.313B, up 29% YoY from $1.016B
  • GAAP diluted EPS $0.38, compared to a loss per share of $(0.51) in Q3 2025
  • Net income of $162M, compared to a net loss of $(200M) in Q3 2025
  • 2026 revenue growth outlook raised to 15%-25%, exceeding prior expectation of up to 10% growth
  • 2026 year-end cash and investments forecast raised to $8.1B-$8.3B from $4.7B-$5.2B
  • R&D expenses decreased 27% YoY to $583M
  • FDA approved mFLUSIVA (seasonal influenza vaccine) in August 2026, the company's fifth approved product globally
  • Positive Phase 3 results for intismeran (mRNA-4157) in melanoma: reduced risk of recurrence or death by 42% vs KEYTRUDA alone
  • Convertible notes offering raised approximately $2.6B in net proceeds in September 2026
  • Litigation settlement with GSK on October 28, 2026, with patent cross-licenses and no payments

Financial Impact

Revenue beat consensus by $422.8M (47.5%); EPS surprise of $1.63 vs consensus estimate of -$1.25; full-year revenue growth outlook raised to 15%-25% from up to 10%

revenueepscash positionguidance

Risk Factors

  • Norovirus vaccine (mRNA-1403) program uncertain after Phase 3 interim analysis failed to meet early success criteria
  • Convertible notes add $3.0B in debt, increasing leverage and potential future dilution
  • Revenue concentration remains heavily dependent on COVID vaccine sales, which are inherently seasonal and subject to demand variability
  • Accounts receivable surged to $1.367B from $184M at year-end 2025, indicating significant uncollected Q3 revenue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
32% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001682852-26-000194
Document: mrna-20261106.htm0001682852-26-000194
Document: 0001682852-26-000194-index-headers.html0001682852-26-000194
Document: 0001682852-26-000194-index.html0001682852-26-000194
Document: 0001682852-26-000194.txt0001682852-26-000194
8-K Data (Synthetic)0001682852-26-000194

Track record

26 reports on MRNA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Viewing Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026